Havrix Junior (Algeldrate, Hepatitis A Virus Antigen (Inactivated))

Havrix Junior is an injectable solution containing the inactivated hepatitis A virus antigen (algeldrate) formulated for intramuscular use. It is a prescription vaccine approved in the European Union for the prevention of hepatitis A infection in children. The product delivers a standardized antigen dose to stimulate active immunity without containing live virus.

Havrix Junior is indicated for active immunisation against hepatitis A in pediatric populations. It is used according to national immunisation schedules to reduce the risk of infection and associated liver disease.

- Primary vaccination of children aged 1 year and older - Completion of a two‑dose series for long‑term protection - Travel to regions with high hepatitis A endemicity - Outbreak control in schools or community settings - Use in children with chronic liver disease when recommended by a healthcare professional

Side effects of Havrix Junior are generally mild and transient, reflecting the body’s immune response to the vaccine. Serious adverse events are rare but should be monitored.

Common: - Pain, redness, or swelling at the injection site - Low‑grade fever within 24‑48 hours - Mild headache or fatigue - Transient muscle aches

Serious: - Severe allergic reaction (anaphylaxis) - High fever persisting more than 48 hours - Neurological symptoms such as seizures (very rare)

Before administering Havrix Junior, certain precautions should be considered to ensure safe use.

- Verify that the child has no known severe allergy to any vaccine component - Defer vaccination in the presence of moderate or severe acute illness - Assess risk versus benefit in children with immunodeficiency conditions - Counsel caregivers about the possibility of mild fever or injection‑site reactions - Document any previous adverse reaction to hepatitis A vaccines - Follow local guidelines for the timing of the second dose

Havrix Junior may interact with other medical products, influencing its safety or effectiveness.

Avoid: - Concurrent administration of live viral vaccines within 4 weeks - Use of immunoglobulin products that could neutralise the vaccine antigen - Administration of blood products immediately before or after vaccination

Use with caution: - Concurrent receipt of other inactivated vaccines (spacing may be recommended) - Use in children receiving immunosuppressive therapy - Co‑administration with antipyretics may mask fever response - Vaccination in children on chronic corticosteroid therapy